HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 946-953

  Zhou, Yan ^a   Yang, Jiyuan ^a   Rhim, Johng S ^b   Kopeček, Jindřich ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Department of Electrical and Computer Engineering   (United States)

Author keywords

Cancer stem progenitor cells; Combination therapy; Cyclopamine; Docetaxel; N (2 hydroxypropyl)methacrylamide (HPMA)

Indexed keywords

COMBINATION THERAPY; CYCLOPAMINE; DOCETAXEL; METHACRYLAMIDES; NARROW MOLECULAR WEIGHT DISTRIBUTIONS; PROSTATE CANCER CELLS; REVERSIBLE ADDITION-FRAGMENTATION CHAIN TRANSFER; THERAPEUTIC BENEFITS;

COPOLYMERS; CYTOLOGY; DRUG PRODUCTS; MOLECULAR WEIGHT DISTRIBUTION; STEM CELLS; TUMORS;

DISEASES;

ANTINEOPLASTIC AGENT; COPOLYMER; CYCLOPAMINE; DOCETAXEL; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL KILLING; CONTROLLED STUDY; DRUG CONJUGATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TUMOR CELL; TUMOR GROWTH; XENOGRAFT;

CANCER STEM/PROGENITOR CELLS; COMBINATION THERAPY; CYCLOPAMINE; DOCETAXEL; N-(2-HYDROXYPROPYL)METHACRYLAMIDE (HPMA);

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; MALE; METHACRYLATES; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS; TAXOIDS; VERATRUM ALKALOIDS;

EID: 84887161387     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.09.005     Document Type: Article

References (42)

1. G.R. MacVicar, and M.H. Hussain Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer Curr. Opin. Oncol. 25 2013 252 260
2. R.L. Grubb, and A.S. Kibel Prostate cancer: screening, diagnosis and management in 2007 Mol. Med. 104 2007 408 412
3. J.P. Medema Cancer stem cells: the challenges ahead Nat. Cell Biol. 15 2013 338 344
4. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
5. D.G. Tang, L. Patrawala, T. Calhoun, B. Bhatia, G. Choy, R. Schneider-Broussard, and C. Jeter Prostate cancer stem/progenitor cells: identification, characterization and implications Mol. Carcinog. 46 2007 1 14
6. M. Shackleton, E. Quintana, E.R. Fearon, and S.J. Morrison Heterogeneity in cancer: cancer stem cells versus clonal evolution Cell 138 2009 822 829
7. J.M. Rosen, and C.T. Jordan The increasing complexity of the cancer stem cell paradigm Science 234 2009 1670 1677
8. J.E. Dick Looking ahead in cancer stem cell research Nat. Biotechnol. 27 2009 44 46
9. F. Yu, H. Yao, P. Zhu, X. Zhang, Q. Pan, C. Gong, Y. Huang, X. Hu, F. Su, J. Lieberman, and E. Song Let-7 regulates self-renewal and tumorigenicity of breast cancer cells Cell 131 2007 1109 1123
10. R.L. Atkinson, M. Zhang, P. Diagaradjane, S. Peddibhotla, A. Contreras, S.G. Hilsenbeck, W.A. Woodward, S. Krishnan, J.C. Chang, and J.M. Rosen Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy Sci. Transl. Med. 2 2010 55 79
11. P.B. Gupta, C.M. Fillmore, G. Jiang, S.D. Shapira, K. Tao, C. Kuperwasser, and E.S. Lander Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells Cell 146 2011 633 644
12. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
13. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 3983 3988
14. A.T. Collins, P.A. Berry, and C. Hyde Prospective identification of tumorigenic prostate cancer stem cells Cancer Res. 65 2005 10946 10951
15. J. Miki, B. Furusato, H. Li, Y. Gu, H. Takahashi, S. Egawa, I.A. Sesterhenn, D.G. McLeod, S. Srivastava, and J.S. Rhim Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens Cancer Res. 67 2007 3153 3161
16. K. Kelly, and J. Yin Prostate cancer and metastasis initiating stem cells Cell Res. 18 2008 528 537
17. Z.A. Wang, and M.M. Shen Revisiting the concept of cancer stem cells in prostate cancer Oncogene 30 2010 1261 1271
18. Y. Teng, X. Wang, Y. Wang, and D. Ma Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells Biochem. Biophys. Res. Commun. 392 2010 373 379
19. S.S. Karhadkar, G.S. Bova, N. Abdallah, S. Dhara, D. Gardner, A. Maitra, J.T. Isaacs, D.M. Berman, and P.A. Beachy Hedgehog signaling in prostate regeneration, neoplasia and metastasis Nature 431 2004 707 712
20. P. Sanchez, A.M. Hernandez, B. Stecca, A.J. Kahler, A.M. DeGueme, A. Barrett, M. Beyna, M.W. Datta, S. Datta, I. Ruiz, and A. Altaba Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling Proc. Natl. Acad. Sci. U. S. A. 101 2004 12561 12566
21. E.E. Bar, A. Chaudhry, A. Lin, X. Fan, K. Schreck, W. Matsui, S. Piccirillo, A.L. Vescovi, F. DiMeco, A. Olivi, and C.G. Eberhart Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma Stem Cells 25 2007 2524 2533
22. R.J. Lipinski, P.R. Hutson, P.W. Hannam, R.J. Nydza, I.M. Washington, R.W. Moore, G.G. Girdaukas, R.E. Peterson, and W. Bushman Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the Mouse Toxicol. Sci. 104 2008 189 197
23. J. Kopeček, and P. Kopečková HPMA copolymers: origins, early developments, present, and future Adv. Drug Deliv. Rev. 62 2010 122 149
24. J. Kopeček Polymer-drug conjugates: origins, progress to date and future directions Adv. Drug Deliv. Rev. 65 2013 49 59
25. Y. Zhou, J. Yang, and J. Kopeček Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells Biomaterials 33 2012 1863 1872
26. J. Liu, P. Kopečková, H. Pan, M. Sima, P. Buhler, P. Wolf, U. Elsässer-Beile, and J. Kopeček Prostate cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates Macromol. Biosci. 12 2012 412 422
27. Z.-H. Peng, M. Sima, M.E. Salama, P. Kopečková, and J. Kopeček Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate specific membrane antigen expressing prostate cancer J. Drug Target. 2013 10.3109/1061186X.2013.833207
28. Y. Zhou, and J. Kopeček Biological rationale for the design of polymeric anti-cancer nanomedicines J. Drug Target. 21 2013 1 26
29. Y. Mitsukami, M.S. Donovan, A.B. Lowe, and C.L. McCormick Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT Macromolecules 34 2001 2248 2256
30. J. Kopeček, and H. Bažilová Poly[N-(2-hydroxypropyl) methacrylamide]. 1. Radical polymerization and copolymerization Eur. Polym. J. 9 1973 7 14
31. P. Rejmanová, J. Pohl, M. Baudyš, V. Kostka, and J. Kopeček Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B Makromol. Chem. 184 1983 2009 2020
32. V. Šubr, and K. Ulbrich Synthesis and properties of new N-(2-hydroxypropyl)methacrylamide copolymers containing thiazolidine-2-thione reactive groups React. Funct. Polym. 66 2006 1525 1538
33. Y. Gu, H. Li, J. Miki, K.H. Kim, B. Furusato, I.A. Sesterhenn, W.S. Chu, D.G. McLeod, S. Srivastava, C.M. Ewing, W.B. Isaacs, and J.S. Rhim Phenotypic characterization of telomerase-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines Exp. Cell Res. 312 2006 831 843
34. S. Wang Anchorage-independent growth of prostate cancer stem cells Methods Mol. Biol. 568 2009 151 160
35. L. Patrawala, T. Calhoun, R. Schneider-Broussard, H. Li, B. Bhatia, S. Tang, J.G. Reilly, D. Chandra, J. Zhou, K. Claypool, L. Coghlan, and D.G. Tang Highly purified CD44 + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells Oncogene 25 2006 1696 1708
36. Y. Nagao, K. Seno, K. Kawabata, T. Miyasaka, S. Takao, and E. Fujita Monitored aminolysis of 3-acylthiazolidine-2-thione: a new convenient synthesis of amide Tetrahedron Lett. 21 1980 841 844
37. A. Dubrovska, J. Elliott, R.J. Salamone, S. Kim, L.J. Aimone, J.R. Walker, J. Watson, M. Sauveur-Michel, C. García-Echeverría, C.Y. Cho, V.A. Reddy, and P.G. Schultz Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma Clin. Cancer Res. 16 2010 5692 5702
38. A. Dubrovska, S. Kim, R.J. Salamone, J.R. Walker, S.-M. Maira, C. García-Echeverría, P.G. Schultz, and V.A. Reddy The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations Proc. Natl. Acad. Sci. U. S. A. 106 2009 268 273
39. A.R. Altaba, P. Sánchez, and N. Dahmane Hedgehog signaling in cancer formation and maintenance Nat. Rev. Cancer 3 2003 903 911
40. A.D. Steg, A.A. Katre, K.S. Bevis, A. Ziebarth, Z.C. Dobbin, M.M. Shah, R.D. Alvarez, and C.N. Landen Smoothened antagonists reverse taxane resistance in ovarian cancer Mol. Cancer Ther. 11 2012 1587 1597
41. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, K.K. Frese, G. Denicola, C. Feig, C. Combs, S.P. Winter, H. Ireland-Zecchini, S. Reichelt, W.J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S.R. Hingorani, P. Huang, S.E. Davies, W. Plunkett, M. Egorin, R.H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, and D.A. Tuveson Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
42. M. Mimeault, S.L. Johansson, J.-P. Henichart, P. Depreux, and S.K. Batra Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells Mol. Cancer Ther. 9 2010 617 630